A Randomized Phase II Study Of Temozolomide Or Temozolomide And Capecitabine In Patients With Advanced Pancreatic Neuroendocrine Tumors
Posted Date: May 15, 2019
- Investigator: Olugbenga Olowokure
- Type of Study: Drug
This study will compare the good and bad effects of temozolomide versus temozolomide plus capecitabine on advanced pancreatic neuroendocrine tumor cancer. Temozolomide and capecitabine have benefited some patients with pancreatic neuroendocrine tumors yet they have never been compared; both arms are
Criteria:
Eligible Patients Must Have A Pancreatic Neuroendocrine Tumor That Has Spread And Is Growing
Keywords:
E2211, Gastrointestinal Can, Gi Cancer, Neuroendocrine Cance, Pancreatic Cancer
For More Information:
Uc Cancer Center
513-584-7698
kastla@ucmail.uc.edu